title: Tumor-Stromal Interactions Influence Radiation Sensitivity in Epithelial- versus Mesenchymal-Like Prostate Cancer Cells.
abstract: HS-27a human bone stromal cells, in 2D or 3D coultures, induced cellular plasticity in human prostate cancer ARCaP(E) and ARCaP(M) cells in an EMT model. Cocultured ARCaP(E) or ARCaP(M) cells with HS-27a, developed increased colony forming capacity and growth advantage, with ARCaP(E) exhibiting the most significant increases in presence of bone or prostate stroma cells. Prostate (Pt-N or Pt-C) or bone (HS-27a) stromal cells induced significant resistance to radiation treatment in ARCaP(E) cells compared to ARCaP(M) cells. However pretreatment with anti-E-cadherin antibody (SHEP8-7) or anti-alpha v integrin blocking antibody (CNT095) significantly decreased stromal cell-induced radiation resistance in both ARCaP(E)- and ARCaP(M)-cocultured cells. Taken together the data suggest that mesenchymal-like cancer cells reverting to epithelial-like cells in the bone microenvironment through interaction with bone marrow stromal cells and reexpress E-cadherin. These cell adhesion molecules such as E-cadherin and integrin alpha v in cancer cells induce cell survival signals and mediate resistance to cancer treatments such as radiation.
authors.affiliation: Department of Urology, Emory School of Medicine, Atlanta, GA 30311, USA.
authors.forename: Sajni
authors.initials: S
authors.lastname: Josson
authors.forename: Starlette
authors.initials: S
authors.lastname: Sharp
authors.forename: Shian-Ying
authors.initials: SY
authors.lastname: Sung
authors.forename: Peter A S
authors.initials: PA
authors.lastname: Johnstone
authors.forename: Ritu
authors.initials: R
authors.lastname: Aneja
authors.forename: Ruoxiang
authors.initials: R
authors.lastname: Wang
authors.forename: Murali
authors.initials: M
authors.lastname: Gururajan
authors.forename: Timothy
authors.initials: T
authors.lastname: Turner
authors.forename: Leland W K
authors.initials: LW
authors.lastname: Chung
authors.forename: Clayton
authors.initials: C
authors.lastname: Yates
references.citation: Br J Cancer. 2007 Apr 23;96(8):1246-52
references.pmid: 17406365
references.citation: Oncogene. 2001 Mar 22;20(12):1525-8
references.pmid: 11313896
references.citation: Prostate. 2010 Apr 1;70(5):518-28
references.pmid: 19918799
references.citation: Surgery. 2002 Aug;132(2):141-8
references.pmid: 12219004
references.citation: J Clin Invest. 2002 Apr;109(7):857-62
references.pmid: 11927611
references.citation: Eur J Pharmacol. 2008 Jun 24;588(1):1-8
references.pmid: 18448095
references.citation: J Cell Sci. 2010 Jan 15;123(Pt 2):266-76
references.pmid: 20048343
references.citation: Prostate. 2008 Nov 1;68(15):1681-8
references.pmid: 18712716
references.citation: Anticancer Res. 2007 Nov-Dec;27(6B):3903-8
references.pmid: 18225549
references.citation: Lab Invest. 2003 Mar;83(3):435-48
references.pmid: 12649344
references.citation: Cancer Biol Ther. 2005 Apr;4(4):365-70
references.pmid: 15846061
references.citation: Clin Exp Metastasis. 2008;25(6):601-10
references.pmid: 18535913
references.citation: Prostate. 2006 Nov 1;66(15):1664-73
references.pmid: 16902972
references.citation: J Biol Chem. 2001 Jul 6;276(27):24661-6
references.pmid: 11323412
references.citation: Curr Opin Genet Dev. 2005 Feb;15(1):97-101
references.pmid: 15661539
references.citation: J Biol Chem. 2003 Jan 17;278(3):1824-30
references.pmid: 12435727
references.citation: Cancer Res. 2001 May 1;61(9):3819-25
references.pmid: 11325858
references.citation: Cancer Res. 2004 Sep 1;64(17):6327-36
references.pmid: 15342422
references.citation: Int J Dev Biol. 2000 Apr;44(3):297-307
references.pmid: 10853826
references.citation: Cell Res. 2008 Aug;18(8):858-70
references.pmid: 18645583
references.citation: Cancer Res. 2006 Dec 1;66(23):11271-8
references.pmid: 17145872
references.citation: Dev Cell. 2001 Jul;1(1):37-49
references.pmid: 11703922
references.citation: Nat Rev Cancer. 2002 Jun;2(6):442-54
references.pmid: 12189386
references.citation: Clin Exp Metastasis. 2008;25(6):621-8
references.pmid: 18600305
references.citation: Prostate. 2008 Jan 1;68(1):92-104
references.pmid: 18008334
references.citation: Cancer. 2000 Jun 15;88(12 Suppl):2995-3001
references.pmid: 10898343
references.citation: Cancer Res. 2002 Dec 1;62(23):6891-900
references.pmid: 12460904
references.citation: Crit Rev Oncol Hematol. 2002 Jan;41(1):11-28
references.pmid: 11796229
references.citation: J Biol Chem. 2003 Dec 12;278(50):50402-11
references.pmid: 14523021
references.citation: EMBO J. 2004 Apr 21;23(8):1739-48
references.pmid: 15057284
references.citation: Hum Pathol. 2001 Jul;32(7):690-7
references.pmid: 11486167
references.citation: Nat Rev Cancer. 2002 Aug;2(8):563-72
references.pmid: 12154349
references.citation: Semin Cancer Biol. 2002 Oct;12(5):373-9
references.pmid: 12191636
references.citation: J Cell Sci. 1995 May;108 ( Pt 5):1945-57
references.pmid: 7544798
references.citation: Adv Cancer Res. 2007;97:225-46
references.pmid: 17419948
references.citation: Mol Ther. 2005 Oct;12(4):634-43
references.pmid: 16039164
references.citation: Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10356-61
references.pmid: 11526241
references.citation: Cancer Res. 2008 Dec 1;68(23):9996-10003
references.pmid: 19047182
references.citation: Cancer Sci. 2006 Feb;97(2):155-62
references.pmid: 16441427
references.citation: Radiat Res. 2009 Sep;172(3):306-13
references.pmid: 19708779